Canine Soft Tissue Sarcoma

Soft-tissue sarcomas (STS) compromise up to 15 percent of all skin tumors in dogs. In a recent study involving STSA-1 canine xenografts in mice, Genelux scientists showed veterinary-grade vaccinia constructs to achieve significant growth inhibition, for the long-term survival of the tumor-bearing mice, and in some cases, near complete tumor regression.